// App-Quantinova.ai

PO1456 : Patient Palatability and Preference Study of Three Potassium Binders in Patients with CKD and Hyperkalemia: Rationale and Design of the APPETIZE Study

Researchers

Presenter

  • James Glen

Principal Investigators

  • Sndergaard Henning

  • Moreno Quinn CarolPatricia

  • Hedman Katarina

  • Karlsson Niklas

  • Hedberg Jonatan

  • Wittbrodt EricT

  • Sabir Ian

  • Tafesse Eskinder

  • Kim Jennifer

  • Allgren RobinL

  • Stjernlf Gunilla

  • Ngrd Mats

  • Chung Hui-Lan

  • Morris JonD

  • Fransson Lars

  • Rutgersson AnnikaIna

  • Wheeler DavidC

Medical Centers

  • AstraZeneca UK Ltd Cambridge Cambridgeshire United Kingdom

  • Danish Kidney Association Copenhagen Denmark

  • AstraZeneca, Gothenburg, Sweden

  • AstraZeneca Gaithersburg Maryland United States

  • AstraZeneca, Taipei, Taiwan

  • AdSAM Gainesville Florida United States

  • Kings College London, London, United Kingdom

Locations

  • United Kingdom

  • Denmark

  • Sweden

  • United States

  • Taiwan

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

Disease

  • Hyperkalemia

Biomarkers

  • N/A

Drug/Treatment

  • Sodium zirconium cyclosilicate

  • Patiromer

Outcome

  • N/A

Study Design

  • Randomized

  • Cross Over

  • Double Blind/Blinded

  • Cross-Sectional

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved